Related Experiment Video

Updated: May 22, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

[Group A streptococcal pneumonia]

Heikki Lukkarinen1, Harri Marttila, Juha Perttilä

  • 1TYKS, lastenklinikka.

Duodecim; Laaketieteellinen Aikakauskirja
|May 24, 2012
PubMed

Insights

Group A betahemolytic streptococcus can cause severe pneumonia with toxic shock syndrome. Early clindamycin use may improve outcomes in this rare but serious infection.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Microbiology

Background:

  • Group A betahemolytic streptococcus (GABHS) is a significant pathogen.
  • GABHS can lead to severe pneumonia, septic shock, and multiorgan failure.
  • This severe presentation is rare and can have delayed diagnosis and treatment.

Observation:

  • This study reports on four patients (two children, two adults) with GABHS pneumonia and toxic shock syndrome.
  • All patients required mechanical ventilation.
  • Three patients received clindamycin in addition to other antibiotics.

Findings:

  • All patients experienced a full recovery from the acute illness.
  • One patient developed permanent optic neuropathy, resulting in vision loss.
  • Clindamycin's role in restraining GABHS toxin production was utilized.

Implications:

  • Prompt diagnosis and aggressive treatment are crucial for GABHS-induced pneumonia and toxic shock syndrome.
  • Clindamycin may be a valuable adjunct therapy due to its effect on toxin production.
  • Healthcare providers should be vigilant for this rare but devastating condition.

More Related Videos

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination09:11

Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination

Published on: September 25, 2014

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: